Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Nov;52(4):1137-1150.
doi: 10.1007/s11239-021-02480-w. Epub 2021 May 23.

Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis

Ioannis Milioglou  1   2 , Ioannis Farmakis  3 , Mandy Neudeker  4 , Zeeshan Hussain  5   4 , Avirup Guha  5   4 , George Giannakoulas  3 , Vassiliki Kotoula  6 , Maria Papaioannou  7
Affiliations
Meta-Analysis

Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis

Ioannis Milioglou et al. J Thromb Thrombolysis. 2021 Nov.

Abstract

Background: Four-factor prothrombin complex concentrate (PCC) is frequently used as a reversal agent for major bleeding in patients on factor Xa inhibitors. Piran et al. reviewed its safety and efficacy for the first time in 2018. However, more studies have been published on the matter since then. The aim of this study is to investigate the efficacy and safety of this use and update this review.

Methods: We systematically searched in Medline, Scopus, and the Cochrane Library from 1/1/2018 to 6/19/2020. A random effects model meta-analysis of proportions was used to study the efficacy of PCC on major bleeding control, mortality and thrombosis incidence.

Results: 33 studies (n = 2568 patients), with the majority of studies being uncontrolled retrospective cohort studies, were included; atrial fibrillation was the main factor Xa inhibitors indication and approximately 62% of patients presented with intracranial hemorrhage. We estimated the pooled proportion outcomes for hemostasis (80%, CI 0.75-0.84), mortality (15%, CI 0.11-0.19) and thromboembolic adverse events (3%, CI 0.02-0.05). High versus low dose PCC did not affect hemostasis or thrombosis. Patients with ICH had higher mortality rates (22%, CI 0.13-0.32). Heterogeneity was significant (Ι2 > 50% with p < 0.05) for all pooled proportional outcomes. The quality of evidence was low given that included studies were not randomized or controlled.

Conclusion: Our study demonstrates the efficacy and safety of the off label use of 4F PCC in major bleeding associated with factor Xa inhibitors. Our data require further validation with future randomized clinical trials.

Keywords: Antidote; Bleeding; Direct oral anticoagulants; Factor xa inhibitors; Reversal.

PubMed Disclaimer

References

    1. Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128(12):1300-1305.e2 - PubMed - PMC
    1. Zareh M, Davis A, Henderson S (2011) Reversal of Warfarin-induced hemorrhage in the emergency department. West J Emerg Med 12(4):386–392 - PubMed - PMC
    1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104
    1. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891

LinkOut - more resources